CHCWM – Cancer & Hematology Centers of West Michigan

SGNSTNV-001 (Seagen, Inc.)

 

SGNSTNV-001 (Seagen, Inc.)

Description:  A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

 

Mechanism of Action:  Antibody drug conjugate to STn, a tumor associated carbohydrate antigen conjugated with MMAE toxin (tubulin disrupting agent).   Highly expressed in mucinous and serous cancers.

Target Patient Population:  All solid tumors.

Study Design:  Drug is administered IV Day 1, 8 and 15 of a 21 day cycle